Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
CERE was delisted on the 31st of July, 2024.
94 hedge funds and large institutions have $3.51B invested in Cerevel Therapeutics Holdings, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 45 increasing their positions, 15 reducing their positions, and 16 closing their positions.
227% more call options, than puts
Call options by funds: $17.4M | Put options by funds: $5.34M
200% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 15
75% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 16
33% more capital invested
Capital invested by funds: $2.65B → $3.51B (+$865M)
15% more funds holding
Funds holding: 82 → 94 (+12)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$280M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$70.6M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$32.8M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$32.7M |
| 5 |
State Street
Boston,
Massachusetts
|
+$23.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$56.4M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$18.3M |
| 3 |
ABG
Ally Bridge Group
New York
|
-$17.3M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$11.2M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$7.02M |
CERE Hedge Fund Activity: Q3 2021 in Review
94 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) for Q3 2021, worth a combined $3.51B — up 33% from $2.65B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new CERE positions and 16 closed out — a net gain of 12 holders — while 45 added to existing stakes and 15 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $280M. The largest seller was RA Capital Management, exiting entirely with an estimated $56.4M sold.
- 94 institutional investors held Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) as of Q3 2021, up from 82 in Q2 2021.
- Funds reported $3.51B of Cerevel Therapeutics Holdings, Inc. Common Stock stock for Q3 2021, up 33% quarter-over-quarter.
- 28 funds opened new Cerevel Therapeutics Holdings, Inc. Common Stock positions in Q3 2021 and 16 closed out, a net change of +12 holders.
- The largest Cerevel Therapeutics Holdings, Inc. Common Stock buyer in Q3 2021 was Fidelity Investments, an estimated $280M added.
- The largest Cerevel Therapeutics Holdings, Inc. Common Stock seller in Q3 2021 was RA Capital Management, an estimated $56.4M sold.
Based on aggregated 13F filings for Q3 2021.